YUMANITY THERAPEUTICS INC (YMTX) Stock News
NASDAQ:YMTX - Nasdaq - US98872L1026 - Common Stock - Currency: USD
YMTX Latest News, Press Relases and Analysis
Inside Kineta's plans after unveiling reverse merger deal
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!
VOD Stock Alert: What to Know as Vodafone Says Goodbye to CEO
Vodafone (VOD) stock is on the move Monday as investors react to the company's CEO stepping down at the end of the year.
Why Are Chinese Stocks Up Today?
Chinese stocks are rallying on Monday as investors get more hopeful news of the country loosening its Covid-19 restrictions.
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after the biopharmaceutical company announced a special dividend.
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
Special dividend estimated to be in range of $1.34 to $1.43 per share Payment of special dividend conditioned upon closing of both Asset Sale and Merger,...
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical...
Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.
Special Meeting of stockholders to approve asset sale and merger to be held on December 13, 2022...
Yumanity Therapeutics, 자산 매각 및 Kineta와의 합병 제안과 관련해 Form S-4 증권신고서 제출
보스턴, Aug. 29, 2022 (GLOBE NEWSWIRE) -- 혁신적인 질환 조절 방식의 퇴행성 신경질환 치료제를 개발하는 임상 단계 바이오 제약사인 Yumanity Therapeutics, Inc.는 미국 증권거래위원회(SEC)에 Form S-4 증권신고서를...
Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on...
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical...
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off another day of trading with an overview of the biggest pre-market stock movers for Thursday!
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates YMTX, GTYH, HR, POLY
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday!
WWDC 2022: 11 Things to Know About This Year’s Apple Developers Event
WWDC 2022 kicks off today and the investors in the tech company will want to keep an eye on the special event from Apple (AAPL).
Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?
Yumanity Therapeutics (YMTX) stock is rocketing higher on Monday after announcing two definitive agreements. including a merger.